Omega-3 (EPA/DHA) vs PCSK9 Inhibitors (Evolocumab, Inclisiran)
Both are used for cardiovascular. Here's how they compare on human evidence, mechanism, safety and availability — in plain English.
| Omega-3 (EPA/DHA) | PCSK9 Inhibitors (Evolocumab, Inclisiran) | |
|---|---|---|
| Human evidence | ★★★★★ | ★★★★★ |
| Legal status | OTC Supplement, FDA Approved | FDA Approved |
| How it works | EPA and DHA incorporate into cell-membrane phospholipids and are converted to anti-inflammatory eicosanoids (resolvins, protectins). They activate PPARα and the fatty-acid receptor FFAR4 (GPR120), lower hepatic triglyceride synthesis, and… | Block PCSK9, the protein that degrades LDL receptors — so LDL receptors survive longer and clear far more LDL. Inclisiran is an siRNA silencing PCSK9, dosed twice yearly. |
| In plain English | These are the fish-oil fats your cell walls are built from. They calm inflammation and lower blood fats — most useful if you don't eat oily fish 2–3× a week. | LDL receptors are the vacuum cleaners that remove bad cholesterol; PCSK9 destroys them. Block PCSK9 and the vacuums keep working — dropping LDL dramatically. Inclisiran is a gene-silencing shot given just twice a year. |
| Bottom line | Rare supplement with strong evidence across heart, joints, and brain. | Most powerful LDL-lowering available; the siRNA form is a genuine leap. |
| Availability | Available over the counter | Available over the counter |
Which is better for cardiovascular?
Both carry a comparable human-evidence rating (★★★★★). Choose on mechanism fit, side-effects, availability and cost rather than evidence strength alone — they work through different mechanisms.
Full breakdowns: Omega-3 (EPA/DHA) · PCSK9 Inhibitors (Evolocumab, Inclisiran).
Common questions
Is Omega-3 (EPA/DHA) or PCSK9 Inhibitors (Evolocumab, Inclisiran) better for cardiovascular?
Both carry a comparable human-evidence rating (★★★★★). Choose on mechanism fit, side-effects, availability and cost rather than evidence strength alone — they work through different mechanisms.
What's the difference between Omega-3 (EPA/DHA) and PCSK9 Inhibitors (Evolocumab, Inclisiran)?
Omega-3 (EPA/DHA): Rare supplement with strong evidence across heart, joints, and brain. — PCSK9 Inhibitors (Evolocumab, Inclisiran): Most powerful LDL-lowering available; the siRNA form is a genuine leap.